Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · November 23, 2022

Myosin Inhibition in Patients With Obstructive HCM Referred for Septal Reduction Therapy: 32-Week Outcomes



Additional Info

Disclosure statements are available on the authors' profiles:

Dose-Blinded Myosin Inhibition in Patients with Obstructive HCM Referred for Septal Reduction Therapy: Outcomes Through 32-Weeks
Circulation 2022 Nov 06;[EPub Ahead of Print], MY Desai, AT Owens, JB Geske, K Wolski, S Saberi, A Wang, MV Sherrid, PC Cremer, SS Naidu, N Smedira, HV Schaff, E McErlean, C Sewell, A Balasubramanyam, K Lampl, AJ Sehnert, SE Nissen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading